The effect of a new medicine (giredestrant or GDC-9545) in patients with ER+ positive breast cancer

A Study of GDC-9545 in Postmenopausal Women With Stage I-III Operable, Estrogen Receptor-Positive Breast Cancer

Cancer
Breast Cancer

Results
Download
Print

Study results

LPS_GO40987_final results_January2022_Dutch_Belgium (PDF, 0.2 MB)

LPS_GO40987_final results_January2022_English (PDF, 0.2 MB)

LPS_GO40987_final results_January2022_French_Belgium (PDF, 0.2 MB)

LPS_GO40987_final results_January2022_Spanish_Spain (PDF, 0.2 MB)

LPS_GO40987_final results_January2022_Spanish_USA (PDF, 0.2 MB)

What is Clinical Research?

In clinical research, volunteers, researchers, and medical professionals work together toward a shared goal: better treatment outcomes for patients. Clinical trials are vital to their process. They are carefully designed and follow approved protocols.

The effect of a new medicine (giredestrant or GDC-9545) in patients with ER+ positive breast cancer

Study results

LPS_GO40987_final results_January2022_Dutch_Belgium (PDF, 0.2 MB)

LPS_GO40987_final results_January2022_English (PDF, 0.2 MB)

LPS_GO40987_final results_January2022_French_Belgium (PDF, 0.2 MB)

LPS_GO40987_final results_January2022_Spanish_Spain (PDF, 0.2 MB)

LPS_GO40987_final results_January2022_Spanish_USA (PDF, 0.2 MB)

What is Clinical Research?

For the latest version of this information please go to www.forpatients.roche.com

Directly contact Roche for questions

Contact the hospital directly

Thank you

Something went wrong

Request a call back

Find participating medical centers and current study status in each of them

The effect of a new medicine (giredestrant or GDC-9545) in patients with ER+ positive breast cancer

For the latest version of this information please go to www.forpatients.roche.com